Introduction: Eating Disorders (ED) represent a significant health concern in the pediatric population due to high morbidity, prolonged hospital stays, and frequent readmissions. Scientific evidence regarding nutritional factors that may influence length of stay or risk of readmission is limited in this population. Objectives: To identify variables associated with longer hospital stays and readmission in pediatric patients with ED admitted to a reference unit in northern Spain. Methods: A retrospective observational study was conducted following STROBE guidelines, including patients under 18 years admitted for ED at a tertiary referral hospital between 2022 and 2025. Nutritional, anthropometric, clinical, evolution-related, and treatment variables were collected. Descriptive analyses, group comparisons according to length of stay and readmission, and logistic regression models were performed to identify associated factors. Results: The study included 75 patients, predominantly female (94.7%), with a mean age of 14.5 years. Twenty-eight percent of patients experienced at least one readmission during the study period. Multivariable regression identified that the use of a nasogastric tube and nutritional supplements was significantly associated with reduced length of stay. In addition, in patients with moderate to severe malnutrition, a recovery greater than 5% according to the Waterlow index was associated with a lower probability of readmission. Although anthropometric differences were observed between groups according to their need for readmission, most were not statistically significant. Conclusions: Nutritional support via nasogastric tube when indicated, the use of nutritional supplements, and a >5% recovery in the Waterlow index in patients with moderate to severe malnutrition are key factors in reducing hospital stay and readmission risk in pediatric patients with ED in our cohort. Isolated laboratory analyses and anthropometric measures showed limited predictive value in this context.

Real-world paediatric data on dupilumab for eosinophilic esophagitis are scarce. To assess the effectiveness and safety of dupilumab in children and adolescents with eosinophilic esophagitis in routine clinical practice. This retrospective multicentre study included patients younger than 18 years treated with dupilumab in 13 Spanish centres between May 2022 and February 2025. Histological, clinical, patient-reported, endoscopic and safety outcomes were assessed at baseline and follow-up endoscopies. Fifty-one patients were included; median age at dupilumab initiation was 13.7 years (IQR, 12.3-15.0). Most had previously received proton pump inhibitors (88.2%), swallowed topical corticosteroids (84.3%) and elimination diets (70.6%). Histological remission occurred in 30/45 patients (66.7%) at first follow-up and 15/19 (78.9%) at final follow-up. Deep histological remission occurred in 55.6% and 63.2%, respectively. Mean peak eosinophil counts decreased from 67 to 8.5 eosinophils/high-power field (p < 0.001). Symptom scores decreased by >60%, asymptomatic patients increased from 17.6% to 78.9%, and mean endoscopic score decreased from 3.2 to 0.9. Adverse events occurred in 18/51 patients (35.3%), all mild. Dupilumab was effective and well tolerated, with sustained histological, clinical and endoscopic improvement.